Awake Together News Aggregator 
Eigentlich ist H5N1 nicht das, woraus für Menschen gefährliche Pandemien gemacht sind.
Dessen ungeachtet wird derzeit, weil in Texas Rinder gefunden wurde, die mit H5N1 infiziert sind, in den gleichgeschalteten Medien mit den selben Texten, denselben Experten und den selben Warnungen Stimmung gemacht.
Es reicht letztlich in einen der abgebildeten Texte, die alle eine Pandemie vorhersagen, die 100Mal, nicht etwa 99 Mal oder 76,4 Mal nein 100 Mal schlimmer sein soll/kann, als die inszenierte SARS-CoV‑2 Pandemie.
Offenkundig gibt es einen Zielwert: 100 Mal schlimmer, anders kann man sich diese blödsinnige Zahlengebung nicht erklären.
“A bird flu pandemic could be ‘100 times worse than Covid’ and kill up to half of everyone it infects, experts have warned — as the White House says it is ‘monitoring’ the situation.
Speaking at a briefing, virus researchers said the H5N1 strain of bird flu may now be getting ‘dangerously close’ to triggering a pandemic.
Multiple cases of the infection in a variety of mammals, including cows, cats and, more recently, humans, are all raising the risk of the virus mutating to become more transmissible, they said.
But others attending the briefing said it was too early to panic because there were still too many unknowns about recent cases to warrant sounding the alarm.
Quelle. Daily Mail
Wir wissen nicht wie es Ihnen geht, aber wenn wir hören, dass das “Demente Haus” eine Situation beobachtet, dann klingeln bei uns alle Alarmglocken ob dessen, was offenkundig wieder vorbereitet wird.
Der Anlass für den “Alarm” unter Experten, wie Suresh Kuchipudi, der an der University of Pittsburg seit Jahren zu H5N1 und SARS-CoV forscht, oder John Fulton, der das “briefing” organisiert hat, das eiligst durchgeführt wurde, um Experten wie Kuchipudi die Gelegenheit zu geben, ihre Sorge, die im Vergleich zu SARS-CoV‑2 100fach schlimmere Sorge mit Blick auf H5N1 an die Öffentlichkeit zu tragen, sind Rinder in Texas.
Ein interessanter Mann, dieser John Fulton, der als Consultant für Pharmafia-Unternehmen tätig ist. Das Consulting war ihm offenkundig nicht genug, weshalb er ein eigenes Unternehmen gegründet hat: BioNiagara, das sich wie folgt präsentiert:
Indes: Das Unternehmen scheint eine Briefkastenfirma zu sein, denn bereits die Webpräsenz, eigentlich das erste, was man als Unternehmen zur Selbstpräsentation einrichtet, noch bevor ein LinkIN-Account aktiviert wird, ist tot:
Wir haben somit die folgende Situation:
- Das “Demente Haus” überwacht die Entwicklung von H5N1
- Ein “Consultant”, der eine Firma gegründet hat, die es nicht zu geben scheint, organisiert ein briefing, an dem, was die Außenwirkung angeht, außer ihm und Kuchipudi niemand teilgenommen zu haben scheint.
- Das wesentliche Ergebnis des briefings ist die Befürchtung, dass dann, wenn es H5N1 gelingen sollte, so zu mutieren, dass es von Mensch zu Mensch übertragbar ist, sich eine Pandemie, die genau 100Mal schlimmer sein wird, als die letzte Pandemie einstellen wird oder könnte.
- Und dieses “Ergebnis” wird flux über die üblichen Hysterie-Kanäle, die sich “Medien” nennen, in die Welt der Konsumenten getragen, um dieselben auf die nächste anstehende “Impfung” vorzubereiten, den nächsten Transfer von Milliarden Euro in Steuergeldern von Steuerzahlern zu Pharmafia-Unternehmen … wer weiß.
Indes, manche scheinen etwas zu wissen, was die meisten von uns, angesichts der wirklich geringen Wahrscheinlichkeit für eine Pandemie, die irgendwo bei 1% pro Jahr liegt, diskret, nicht kontinuierlich, nicht wissen:
Quelle: Concerned Citizen
Nun gibt es mit H5N1 ein Problem:
Das Virus ist derzeit nicht von Mensch zu Mensch übertragbar. Daran ändert auch die Tatsache, dass H5N1 vereinzelt in anderen Säugetieren, Rindern, einer Ziege, einem Hund, selbst einem Eisbären gefunden wurde, nichts. Einzelfälle, die derzeit auf Basis der schon während COVID-19 so populären Falschinformation der Zoonose, der Übertragung von Tier zu Mensch gehypt werden, um Angst und Schrecken zu verbreiten und die Öffentlichkeit auf die nächste Pandemie, die offenkundig bösartige Kreise bereits in der Warteschleife kreisen lassen, vorzubereiten.
Derzeit trägt H5N1 nicht umsonst die Bezeichnung “Avian Flu / Vogelgrippe”, denn die Opfer, die sich das Virus sucht, sind Vögel und von Vögeln gelangt ein Virus nur unter sehr spezifischen Bedingungen überhaupt in den Organismus von Menschen. Um gefährlich zu werden, bedarf es eines Zwischenwirts, in dem das Virus in einer Weise mutiert, die eine Übertragung von Mensch zu Mensch möglich macht. Und das ist nicht so einfach: Nur zur Erinnerung: Bis heute ist der Zwischenwirt, der notwendig ist, um SARS-CoV‑2 von Fledermäusen auf Menschen übertragen zu können, nicht gefunden worden. Was natürlich kein Wunder ist, wurde SARS-CoV‑2 doch mit US-amerikanischer Förderung im von Frankreich mitgebauten Wuhan-Institute of Virology entwickelt und (unabsichtlich) freigesetzt, vielleicht auch, um die Performanz der eigens eingefügten Furin-Cleavage-Site, die die Übertragung von Mensch zu Mensch nahezu perfektioniert hat, zu prüfen.
Das bringt uns zurück zu H5N1 und einer eher beunruhigenden Gemeinsamkeit zwischen H5N1 und SARS-CoV‑2: Chinesische BioSafety-Labore. Holen wir etwas weiter aus [nur kurz]
H5N1 ist eine Ribonukleinsäure, wie SARS-CoV‑2, hat aber im Gegensatz zu SARS-CoV‑2 eine negative Polarität. H5N1 hat, wie die Tabelle zeigt, auch Menschen befallen, Menschen, die sich in engem Kontakt mit Vögeln befunden haben. Die folgende Tabelle der WHO gibt den aktuellen Stand der H5N1-Erkrankungen unter Menschen wieder:
H5N1 ist vor allem in Asiatischen Ländern und in Ägypten ein Problem, indes eines, das seit 2019 verschwunden ist, denn H5N1 ist in seiner weltweiten Verbreitung im Wesentlichen auf die Jahre vor 2019 beschränkt. Offenkundig ist es SARS-CoV‑2 gelungen, auch H5N1 weltweit auszurotten … Wie auch immer: Seit 2003 sind weltweit 868 Menschen an einer Avian Flu, an H5N1 erkrankt, davon sind 457 verstorben. Die Case Fatality Rate beträgt demnach 52,7%. Das macht H5N1 zu einem der für Menschen gefährlichsten Viren, die derzeit bekannt sind.
Zum Glück ist H5N1 nicht von Mensch zu Mensch übertragbar.
Das heißt, es war eigentlich nicht übertragbar. Denn bereits im Jahr 2013 haben Chinesische Forscher des Harbin Veterinary Research Institute in Science einen Beitrag veröffentlicht, in dem sie davon berichten, dass sie mit H5N1 herumgespielt haben.
Was die Chinesischen Forscher hier getan haben, ist leicht zu beschreiben: Sie haben ein Hybrid aus zwei Viren, aus H5N1 und H1N1 geschaffen, von dem man annehmen kann, dass es nun Eigenschaften beider RNA-Stränge, von H5N1 und H1N1 kombiniert.
H5N1 ist, wie die Tabelle oben zeigt, ein aggressiver Killer. Wer an H5N1 erkrankt, hat eine Überlebenswahrscheinlichkeit von 47%. Aber, wie gesagt, H5N1 ist nicht von Mensch zu Mensch übertragbar. H1N1 ist von Mensch zu Mensch übertragbar. H1N1, besser bekannt als Influenza A Subtypus H1N1 ist Nachfolger des Virus, das 1918/19 weltweit rund 50 Millionen Menschen getötet hat, der spanischen Grippe. Seit 1976 kehrt es regelmäßig wieder, 2009 als Pandemie. H1N1 ist hoch ansteckend zwischen Menschen, hat aber nur eine Letalität von 0,1% bis 0,2%, d.h. nicht viele sterben, 99,8% derjenigen, die an H1N1 erkranken, überleben die Erkrankung.
Mit anderen Worten, die chinesischen Forscher haben ein Virus, das für Menschen in mehr als der Hälfte der Fälle der Erkrankung tödlich verläuft, aber nicht von Mensch zu Mensch übertragen werden kann, mit einem Virus gemischt, das sehr leicht von Mensch zu Mensch übertragen werden kann, sie haben ein Virus geschaffen mit dem Potential rund die Hälfte der Menschheit auszurotten.
Das war im Jahr 2013.
Hualan Chen, hauptverantwortlich für die Forschung, hat damals gegenüber der britischen Zeitung “The Independent” erklärt, dass die Studie zeige, dass es H5N1 gelingen könne, von Mensch zu Mensch übertragen zu werden, wobei die Übertragung, wie die Studie aus Harbin zeigt, aerosol erfolgen kann, also durch winzige Tröpfchen, vor denen man sich kaum schützen kann. Die Ergebnisse, so Chen weiter, zeigten, dass H5N1 die Ursache einer Pandemie sein könne.
Die Forschung aus China hat 2013 zu einem Aufschrei der Entrüstung geführt. Lord May of Oxford, der ehemalige Präsident der Royal Society und ehemalige Chief Scientist der Britischen Regierung hat gegenüber dem Independent von einer unverantwortlichen Studie gesprochen:
“They claim they are doing this to help develop vaccines and such like. In fact, the real reason is that they are driven by blind ambition with no common sense whatsoever.”
Simon Wain-Hobson, Professor am Pasteur Institut in Paris hält es für hochwahrscheinlich, dass das in einem chinesischen Labor neugeschaffene Virus von Mensch zu Mensch übertragen werden könne und eine hohe Lethalität habe. Er hält es für ausgeschlossen, dass die Forschungsergebnisse als Grundlage für die Entwicklung eines Impfstoffes benutzt werden können, wie die Chinesischen Forscher behaupten:
“The virological basis of this work is not strong. It is of no use for vaccine development and the benefit in terms of surveillance for new flu viruses is oversold.”
Mit anderen Worten, die Erschaffung eines neuen Super-Virus, das so tödlich wie H5N1 für Menschen ist und so übertragbar wie H1N1 zwischen Menschen, hat keinerlei wissenschaftlichen Wert. Das an sich ist schon schlimm genug, aber es kommt noch hinzu, dass bereits 2013 chinesische Labore im Gespräch waren, weil sie nicht in der Lage waren, grundlegende Sicherheitsstandards einzuhalten:
“The record of containment in labs like this is not reassuring. They are taking it upon themselves to create human-to-human transmission of very dangerous viruses. It’s appallingly irresponsible”, hat Lord May 2013 bereits geurteilt.
Wie das Leak aus Wuhan zeigt, ist es um die Sicherheit Chinesischer Labore in den letzten Jahren nicht besser bestellt, sofern man glaubt, dass SARS-CoV‑2 unabsichtlich freigesetzt wurde. Indes: Die Tatsache, dass Virenstämme in Laboren entwickelt werden, die es in der Natur nicht gibt, vermutlich nie geben wird, wie SARS-CoV‑2 oder ein Hybrid aus H5N1 und H1N1, Viren, deren wissenschaftlicher Wert so gering ist, dass man ihn nicht mehr bestimmen kann, trägt einen sehr schalen Beigeschmack von Biowaffe mit sich. Eine Verwendung als Biowaffe, um die Menschheit zu dezimieren, ohnehin ein Lieblingsprojekt der Globalisten, ist die einzige rationale Erklärung dafür, dass Junk wie der berichtete in Laboren entwickelt wird.
Indes muss man nicht davon ausgehen, dass die Menschheit ausgerottet werden soll, man soll auch Gier als Motiv hinter der Entwicklung von leicht übertragbaren Varianten von H5N1 nicht ausschließen, zumal eine Suche in der Datenbank “clinicaltrials.gov”, eine Unmenge von klinischen Trials, die der Suche nach einem Impfstoff gegen H5N1, das es geschat hat, seit 2003 868 Menschen zu infizieren, gewidmet sind. Eher eine müde Begründung für 198 klinische Trials, in denen bereits Impfstoffe getestet werden, die für Kinder gedacht sind, gegen H5N1…
Für wie lukrativ Pharmaunternehmen und ihre Sponsoren beim US-Government die Entwicklung eines Impfstoffes gegen H5N1 halten, zeigt die folgende Liste der laufenden bzw. abgeschlossenen klinischen Trials, in denen ein potentieller Impfstoff gegen H5N1 getestet wurde oder wird. Vor allem Novartis, GlaxoSmithKlyne, aber auch “Faucis” NIAID und Moderna bemühen sich, einen Impfstoff auf Vorsehung zu entwickeln, für den Fall, dass H5N1 eines Tages von Mensch zu Mensch übertragbar sein sollte – eigentlich eine 1 in einer Million Chance, aber heutzutage, da Profit offensichtlich mit allen Mittel durchgesetzt werden soll und kann, kann man sich nicht mehr sicher sein, dass nicht irgendwie bei der Übertragbarkeit nachgeholfen werden wird …
| NCT Number | Study Title | Sponsor |
| NCT03038776 | Recombinant H7 Hemagglutinin Influenza Vaccine Trial | Vaxine Pty Ltd |
| NCT00530660 | Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501) | Ology Bioservices |
| NCT02743676 | A Retrospective, Observational Registry of Participants With Avian Influenza Infection | Hoffmann-La Roche |
| NCT04669691 | A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine | Seqirus |
| NCT03651544 | The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation |
| NCT01142362 | Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults | Inovio Pharmaceuticals |
| NCT01107262 | Avian Influenza Studies In Lebanon | St. Jude Children’s Research Hospital |
| NCT00311480 | Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects | Novartis |
| NCT01258062 | Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults | Ology Bioservices |
| NCT00417560 | Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses | Centers for Disease Control and Prevention |
| NCT03834376 | Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection | Janssen Research & Development, LLC |
| NCT03472976 | H5N1 With or Without Topical Aldara in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01184976 | Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males | GeneOne Life Science, Inc. |
| NCT00900991 | Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children | Sinovac Biotech Co., Ltd |
| NCT01698060 | Immunogenicity of ND1.1 by Delivery Directly to the Ileum | Vaxart |
| NCT03755427 | A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine | Shanghai Institute Of Biological Products |
| NCT00489931 | Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00884182 | Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children | Sanofi Pasteur, a Sanofi Company |
| NCT00841763 | Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects | Novartis |
| NCT02078674 | A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1 Adjuvant |
Novavax |
| NCT00783926 | Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) | Ology Bioservices |
| NCT00640874 | A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza | Kirby Institute |
| NCT03682120 | Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59® Adjuvant to Prevent Avian Influenza | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01594320 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 | Novavax |
| NCT03745274 | Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults | AVIR Green Hills Biotechnology AG |
| NCT00439530 | Pharmacologic Study of Oseltamivir in Healthy Volunteers | Mahidol University |
| NCT02839330 | A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age | Seqirus |
| NCT00337896 | T and B Cell Response to Avian Flu Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00439335 | Higher Dose Intradermal H5 Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00516035 | Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00478816 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines | Novartis Vaccines |
| NCT00537524 | Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years | Novartis Vaccines |
| NCT01044095 | Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus | Armed Forces Research Institute of Medical Sciences, Thailand |
| NCT01995695 | Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00347672 | Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00545701 | Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults | Sanofi Pasteur, a Sanofi Company |
| NCT01897701 | A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 | Novavax |
| NCT00519389 | Safety, Reactogenicity and Immunogenicity of an H5N1 VLP | Novavax |
| NCT02586792 | H7N9 Boost in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02095444 | Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection | S‑Evans Biosciences Co., Ltd. |
| NCT01323946 | Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children | GlaxoSmithKline |
| NCT00695669 | A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18–64 | GlaxoSmithKline |
| NCT00848029 | Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules | Novartis Vaccines |
| NCT00415129 | Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly | Sanofi Pasteur, a Sanofi Company |
| NCT01382329 | H5N1 Vaccine Study in Japanese Adults | Ology Bioservices |
| NCT00841646 | Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects | Novartis Vaccines |
| NCT01573312 | H5N1 Vaccination With and Without AS03: Systems Biology Analysis | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00382980 | Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00488046 | Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00680069 | H5N1 (Clade 2) Vaccination of Adults and Elderly | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00240968 | H5 Booster After a Two Dose Schedule | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01640691 | Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults | Adimmune Corporation |
| NCT01236040 | Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 – 49 Years Old | GlaxoSmithKline |
| NCT02719743 | A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age | GlaxoSmithKline |
| NCT00719043 | Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years | GlaxoSmithKline |
| NCT03739229 | Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine | Research Institute of Influenza, Russia |
| NCT01657929 | H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers | Access to Advanced Health Institute (AAHI) |
| NCT00532792 | A/H5N1 Dose Ranging Study With Adjuvant Patch | Intercell USA, Inc. |
| NCT00895544 | Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults | Ology Bioservices |
| NCT01942265 | H7N9 Mix and Match With AS03 and MF59 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02480101 | Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine | Research Institute of Influenza, Russia |
| NCT01147068 | Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults | Protein Sciences Corporation |
| NCT01766921 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects | Novartis Vaccines |
| NCT02151344 | Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03312231 | Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00311727 | Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01086657 | An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re… | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03581903 | A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00519064 | Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases | Novartis Vaccines |
| NCT02206464 | H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo… | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03369808 | A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine | Shanghai Institute Of Biological Products |
| NCT01195038 | Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults | UMN Pharma Inc. |
| NCT00561184 | Safety and Immunogenicity of a Booster Dose of ‑H5N1 Influenza Vaccine | Novartis Vaccines |
| NCT01675284 | A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine | Medigen Biotechnology Corporation |
| NCT00640302 | A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza | Kirby Institute |
| NCT02680002 | Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant | Biomedical Advanced Research and Development Authority |
| NCT01052402 | Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents | Ology Bioservices |
| NCT00110279 | Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02091908 | Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions | Seqirus |
| NCT00230750 | Inactivated Influenza A/H5N1 Vaccine in the Elderly | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00853255 | Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01403155 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 | Inovio Pharmaceuticals |
| NCT00297050 | Safety and Dose Study of Peramivir for Influenza Treatment | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03345043 | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | ModernaTX, Inc. |
| NCT00755703 | Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. | Altimmune, Inc. |
| NCT01045564 | Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure | GlaxoSmithKline |
| NCT00240903 | Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02335164 | A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults | Vaxine Pty Ltd |
| NCT03014310 | H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00711295 | Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups | Ology Bioservices |
| NCT01250795 | Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults | Fraunhofer, Center for Molecular Biotechnology |
| NCT01928472 | Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years | Novartis Vaccines |
| NCT00908687 | A/H5N1/LT Dose Ranging Study | Intercell USA, Inc. |
| NCT00298233 | High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00434733 | Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects | Novartis |
| NCT00382187 | Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults | Novartis Vaccines |
| NCT00280033 | H5 Adult – Chiron Study of Bird Flu Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00660257 | Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine | Sinovac Biotech Co., Ltd |
| NCT01086566 | Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05422326 | A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed | Seqirus |
| NCT00868218 | Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults | Rebecca Cox |
| NCT01074736 | Host Genetic Susceptibility to Avian Influenza A/H5N1 | South East Asia Infectious Disease Clinical Research Network |
| NCT02295813 | Safety and Pharmacokinetics Study of FBF001 | Fab’entech |
| NCT00694213 | Pandemic Influenza Plasmid DNA Vaccines (Needle-Free) | Vical |
| NCT00311649 | Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01999842 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age | GlaxoSmithKline |
| NCT01938742 | H7N9 Mix and Match With MF59 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01443936 | Experimental AD4-H5-VTN Vaccine in Healthy Volunteers | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00402649 | Open-Label Study of H5 Vaccine in Participants of Protocol 04–077 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02171819 | Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU‑A/H5N1) – Phase 1 | Institute of Vaccines and Medical Biologicals, Vietnam |
| NCT01511419 | Safety Trial of Live Attenuated Influenza (H7N3) Vaccine | PATH |
| NCT00133536 | A/H5N1 Vaccine in Healthy Children Aged 2–9 Years | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00310206 | H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00294099 | H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00517517 | Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) | Ology Bioservices |
| NCT00296634 | H5 Vaccine Alone or With Adjuvant in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02177734 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age | GlaxoSmithKline |
| NCT01353534 | Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine | Intercell USA, Inc. |
| NCT01317758 | H5N1 Mix and Match With AS03 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00912496 | Booster Trial to 07–0019 With A/Anhui/05 With and Without MF59 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01596725 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 | Novavax |
| NCT02691130 | Assess the Safety and Immunogenicity of M‑001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults | BiondVax Pharmaceuticals ltd. |
| NCT02229357 | Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine | Mahidol University |
| NCT01776541 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults | Novartis Vaccines |
| NCT01037634 | Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01578317 | Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00115986 | A/H5N1in Adult – Aventis | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01443663 | Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00664417 | Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine | Sanofi |
| NCT03738241 | 2017 A/H7N9 IIV Revaccination | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02624219 | H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03283319 | Panblok H7 Vaccine Adjuvanted With AS03 or MF59 | Biomedical Advanced Research and Development Authority |
| NCT00349141 | Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) | Ology Bioservices |
| NCT01310413 | Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age | GlaxoSmithKline |
| NCT00812019 | Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18–40 Years Old) | Seqirus |
| NCT05397119 | A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults | BlueWillow Biologics |
| NCT01298206 | Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon | St. Jude Children’s Research Hospital |
| NCT01389466 | Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers | Green Cross Corporation |
| NCT00481065 | Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects | Novartis |
| NCT01379937 | A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals’ Influenza Vaccine in Children | GlaxoSmithKline |
| NCT01910519 | Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00814385 | Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 | University Hospitals, Leicester |
| NCT00491985 | Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children | Sanofi Pasteur, a Sanofi Company |
| NCT00408109 | Safety Study of Avian Flu Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00771615 | Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged 18–64 Years | GlaxoSmithKline |
| NCT01656356 | Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers | Mahidol University |
| NCT02612909 | A Safety and Immunogenicity Study of IVACFLU‑A/H5N1 | Institute of Vaccines and Medical Biologicals, Vietnam |
| NCT02107807 | Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine | Seqirus |
| NCT00457509 | Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults | Sanofi Pasteur, a Sanofi Company |
| NCT00428753 | China Case Control Avian Influenza | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00703053 | H5N1 Priming and Boosting Strategies | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01317745 | H5N1 Mix and Match With MF59 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01676675 | A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults | Jiangsu Province Centers for Disease Control and Prevention |
| NCT00397215 | Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age | GlaxoSmithKline |
| NCT00620815 | Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above | Novartis Vaccines |
| NCT00462215 | Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) | Ology Bioservices |
| NCT01774032 | H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older | Ology Bioservices |
| NCT01150552 | Studies of Avian Influenza Transmission to Humans in Egypt | St. Jude Children’s Research Hospital |
| NCT00709800 | Pandemic Influenza Plasmid DNA Vaccines (Needle) | Vical |
| NCT01658800 | Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 | VaxInnate Corporation |
| NCT00734175 | Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00311675 | St. Jude Open Label H5 Trial | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00922259 | Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03318315 | Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00380237 | Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03330899 | Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil | Butantan Institute |
| NCT03497845 | Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 | Biomedical Advanced Research and Development Authority |
| NCT02274545 | Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01335347 | Safety Study of an Oral Vaccine to Prevent Avian Influenza | Vaxart |
| NCT00309647 | Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age | GlaxoSmithKline |
| NCT00980447 | Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults | UMN Pharma Inc. |
| NCT00984945 | Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults | Medicago |
| NCT00356798 | Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects | Sinovac Biotech Co., Ltd |
| NCT01006798 | Safety and Immunogenicity of Replication-Competent Adenovirus 4‑vectored Vaccine for Avian Influenza H5N1 | Emergent BioSolutions |
| NCT00319098 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above | GlaxoSmithKline |
| NCT01416571 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Monovalent Pandemic H5N1 Vaccine in Adults | GlaxoSmithKline |
| NCT00428493 | Prospective Study of AI H5N1 in China | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02957656 | Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02153671 | Immunogenicity of H5N1 Vaccine Following H5N2 | PATH |
| NCT00914771 | Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects | Novartis Vaccines |
| NCT00383071 | Development of Immune Globulin Treatment for Avian Flu | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01560793 | Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 Years | VaxInnate Corporation |
| NCT01776554 | Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children | Novartis Vaccines |
| NCT04789577 | A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals’ Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older | GlaxoSmithKline |
| NCT02213354 | H7N9 Mix and Match With MF59 in Healthy Elderly Persons | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03701061 | Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response | Emory University |
| NCT02436928 | A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects | Medigen Vaccine Biologics Corp. |
| NCT03196661 | Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population | Hualan Biological Bacterin Co. Ltd. |
| NCT01788228 | Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure | GlaxoSmithKline |
| NCT00640211 | A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B | Kirby Institute |
| NCT03816878 | Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00776711 | Vaccine for Prevention of Bird Flu | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03589807 | 2013/2017 H7N9 Prime-Boost Interval | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02251288 | A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00900588 | Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents | Sinovac Biotech Co., Ltd |
| NCT01987011 | Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers | Green Cross Corporation |
| NCT02921997 | H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01911754 | Japanese Pediatric H5N1 Vaccine Study | Ology Bioservices |
Quelle Feature Image: Poultry World
Zuerst erschienen bei ScienceFiles.org.
The post H5N1-Vogelgrippe: Ist die nächste Inszenierung einer Pandemie bereits in der Warteschleife? appeared first on Die Unbestechlichen.
